Contract Services, Formulation and Drug Delivery

The need for preclinical testing expertise is growing as molecular complexity increases.

A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.

Despite the successes that have already been achieved with emerging therapy development and manufacturing, companies are still facing numerous challenges.

WuXi XDC will provide end-to-end services to support Boostimmune’s discovery of novel bioconjugates.

Hope is on the horizon as novel solutions and improvements aimed at benefitting the drug development process with the right framework are coming to the fore.

Shifting toward more technological solutions and ensuring a greater understanding of the workforce’s needs will give both CROs and sponsors a market advantage.

The Vault Quality Suite will help Adare simplify its quality operations across its sites in the United States, France, and Italy.

Under two new agreements, Societal CDMO will offer analytical, technical transfer, formulation, manufacturing, and packaging services for novel therapeutics.

While a variety of innovations have already impacted the drug delivery landscape, improving sustainability and having the ability to make smaller volumes of drug products still require work.

Experts divulge where the industry is outsourcing most frequently, when companies should outsource more, and when performing tasks in-house might be best.

Demand for outsourced services of technical R&D activities is increasing.

CDMOs offer expertise and customization options for sponsors of orphan drugs.

Experience is an invaluable asset for outsourcing partners, particularly as more challenging method development services are in demand.

Shifting demands from industry innovators is leading to an increased need for flexible and agile outsourcing partners offering broad and integrated models.

The CRO market will see greater consolidation by both financial buyers looking to consolidate smaller players and larger CRO players wanting to expand into value-added specialty service areas.

The companies have entered into an agreement to develop processes for a novel immunotherapy protein.

Outsourcing method development offers multiple benefits to companies, including access to experience and expertise, streamlined costs, and development time efficiencies.

Manufacturers and the US government are investing heavily in traditional and non-traditional forms and materials to ensure supplies of containers and delivery devices for COVID-19 treatments and vaccines.

Contract service organizations can offer biopharma companies early insight into dangers that may hinder a drug’s later development.

Alcami Biologics formed to meet market demands for biological drug development services.

The merged companies will provide histopathology services in the research and pre-clinical therapeutics markets.

ADC Biotechnology will invest downstream formulation, fill/finish capabilities, and Lock-Release conjugation technology.

Formulation issues cause significant drug project delays and project failures, according to a 2018 survey conducted by Informa Pharma Intelligence, Rentschler Biopharma, and LEUKOCARE.

The company says the new equipment will reduce sample turnaround times and increase variant detection quality and accuracy.

Vetter anounced the Open Innovation Challenge to examine the applicability of digital trends to injection systems.

ADC Bio experts warn of impending problems in the ADC pipeline with millions wasted in development costs.

The company has officially opened a local brand office in South Korean to support its existing business in the region.

Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.

Catalent Applied Drug Delivery Institute announced a partnership with Rutgers University to examine the challenges of pediatric drug formulation and delivery.

Microdermics will focus on product development and clinical activities of new drug delivery methods, while Vetter’s primary role will be in the fill and finish aspect.